Clinical Trials Logo

Dipeptidyl-peptidase-4 clinical trials

View clinical trials related to Dipeptidyl-peptidase-4.

Filter by:
  • None
  • Page 1

NCT ID: NCT03046576 Completed - Clinical trials for Coronary Angiography

Prognostic Value of Plasma DPP4 Activity in ST-elevation Myocardial Infarction Patients

Start date: January 1, 2013
Phase: N/A
Study type: Observational

Increased plasma DPP4 activity (DPP4a) could predict both subclinical and new-onset atherosclerosis, and our previous study has found that the DPP4a was significantly lower in MI patients compared with patients having chest pain or unstable angina alone, and DPP4a is associated with no-reflow and major bleeding events in STEMI patients during hospital stay. As no-reflow phenomenon and major bleeding events independently associates with a worse in-hospital and long-term prognosis. One may speculate that the DPP4a is associated with long-term follow-up adverse cardiovascular events in these patients.The hypothesis was tested in this study.

NCT ID: NCT02849691 Completed - Bleeding Clinical Trials

Plasma Dipeptidyl-peptidase-4 Activities With No-reflow and Bleeding

Start date: January 2014
Phase: N/A
Study type: Observational

Dipeptidyl-peptidase-4 (DPP4) is an important regulator of incretins and inflammation, and participates in the pathophysiological process of acute myocardial infarction (AMI). However clinical data of DPP4a in AMI patients is sparse. This study was to investigate the role of plasma DPP4 activity (DPP4a) in patients with ST-segment elevation myocardial infarction (STEMI) treated with percutaneous coronary intervention (PCI). This was a analysis of consecutive patients conducted at a tertiary referral center from January 2014 to October 2015. The investigators included 747 STEMI-patients, treated with PCI from January 2013 to October 2015. Blood samples were collected immediately at admission. The patients were divided into four groups according to DPP4a quartile.